Reply to van der Hoek and Berkhout, Ebihara et al., and Belay et al.

To the Editor—The discovery of the human coronavirus (HCoV) we designated the “New Haven coronavirus” (HCoV-NH) was the result of a deliberate search for previously unknown HCoVs and was made without a priori knowledge of HCoV-NL63 [1] and HCoV-NL [2], the 2 HCoVs from The Netherlands that were recently described, and before the report of the discoveries of these viruses. Unlike HCoV-NL63 and HCoV-NL, which were initially identified in cell cultures, HCoV-NH was discovered by screening respiratory tract specimens with molecular probes. These probes targeted the sequences of the replicase 1a gene that are conserved among human, avian, and mammalian CoVs. Therefore, it is not surprising—perhaps it is predictable—that this region of the replicase 1a gene is highly conserved between HCoV-NH and HCoV-NL63. Until full genomic sequencing of HCoV-NH is complete, we believe that it is premature to state that HCoV-NH, HCoV-NL63, and HCoV-NL are the same virus. Nonetheless, as we clearly acknowledge in our study [3], it is likely that these viruses are closely related.

van der Hoek and Berkhout raise the issue of nomenclature [4]. Whether HCoV-NH and HCoV-NL63 are strains of the same species of virus remains to be determined. Sequence comparison between viruses is only one of many criteria used to differentiate between viral species [5]. In fact, the International Committee on Taxonomy of Viruses has established no specific guidelines to address the issues of nomenclature and categorization of potentially closely related viruses that have been identified independently [5,6]. Undoubtedly, this will continue to be an issue as new viral pathogens are identified.

We disagree with van der Hoek and Berkhout that the naming of HCoV-NH “needlessly complicates the HCoV literature” [4]. Rather, we believe that the identification of HCoV-NL63 and HCoV-NL by cell culture and genome amplification techniques and the identification of HCoV-NH by use of molecular probes exemplify the recent advances in methods to identify previously unrecognized viruses. As the full genomes of these viruses are described, the clarification of the nomenclature will follow.

We believe it is important to attempt to replicate in different populations our finding of the association between HCoV-NH infection and Kawasaki disease, and we appreciate the letters from Ebihara et al. [7] and Belay et al. [8]. We would be interested to know whether proper controls were included to demonstrate the integrity of the RNA that was used in the amplification assays by Ebihara et al. We agree with Belay et al. that the timing of sample collection and the type of sample screened (nasal vs. pharyngeal) may explain the discrepancy in results between their study and ours. Furthermore, more than one etiological agent may be linked to Kawasaki disease. Nonetheless, we are intrigued by the study by Graf that suggests the presence of a peptide, corresponding to the spike protein of HCoV-NL63, in tissue from individuals with Kawasaki disease [9]. These findings further support the association between HCoV-NH and Kawasaki disease.

Frank Esper,1 Eugene D. Shapiro,1,2,3 Marie L. Landry,4 and Jeffrey S. Kahn1,2
1Department of Pediatrics, Division of Infectious Diseases, 2Department of Pediatrics, Division of General Pediatrics, and 3Departments of Epidemiology and Public Health and Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut

References

Reply to van der Hoek and Berkhout

To the Editor—In my Editorial Commentary [1], I certainly did not intend to detract from the novelty and importance of the findings by van der Hoek et al. [2] in early 2004. As I pointed out clearly, Esper et al. [3] were unaware of van der Hoek et al.’s discovery of the Netherlands strain of human coronavirus (HCoV-NL63) when they designed their polymerase chain reaction (PCR) and apparently also when they first found the HCoV they designated.
the “New Haven coronavirus” (HCoV-NH). I described the methodology used by Esper et al. for finding the virus as “logical, intelligent, and highly original” (p. 489)—as was, in fact, the different methodology used by van der Hoek et al.—and the development of this methodology seemed to me at least as notable an accomplishment as the discovery of a “new” virus. In my Editorial Commentary, I also stated that HCoV-NH appeared to be similar to, and quite possibly (although not certainly) the same as, HCoV-NL63. The published sequence of HCoV-NH, which covered only a portion of a single gene from this very large genome, did not seem to be adequate to make a final decision on this point, however.

Regardless of whether HCoV-NH turns out to be, from a taxonomic viewpoint, the same as HCoV-NL63, the findings by Esper et al. are exciting and extend our knowledge of respiratory HCoVs, particularly in relation to pediatric disease. In addition, broader application of their PCR methodology offers to us the hope that we will find additional members of this family of viruses.

Kenneth McIntosh
Division of Infectious Diseases, Children’s Hospital Boston, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts

References

Reprints or correspondence: Dr. Kenneth McIntosh, Div. of Infectious Diseases, Children’s Hospital Boston, 300 Longwood Ave., Enders 609, Boston, MA 02115 (kenneth.mcintosh@tch.harvard.edu).

The Journal of Infectious Diseases 2005; 192:353–4
© 2005 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2005/19202-0025$15.00